Moberg Derma AB and MedPharm Ltd today announce a license and distribution agreement for the development, marketing and sales of new dermatology products that will combine Moberg Derma’s Kaprolac® platform with MedPharm’s MedSpray™ technology. According to the agreement, MedPharm will be eligible for royalty payments.
Moberg Derma obtains the exclusive rights to worldwide manufacturing, distribution and sales and have the option to develop three products based on MedSpray™. Moberg Derma will be responsible for the clinical development and registration of the new products. “This collaboration with MedPharm enables us to broaden our pipeline with highly innovative and commercially attractive products. There are important synergies between MedPharm’s formulation technology and Moberg’s therapeutic concepts”, says Peter Wolpert, CEO of Moberg Derma AB.
“We have great expectations on this collaboration as MedPharm’s know-how and experience add significant value to our development portfolio.” “I am extremely pleased that we will be working with Moberg Derma to develop innovative dermatology products utilizing our MedSpray™ drug delivery system.
This spray-on film technology will produce patient-friendly, elegant products. Combining our Patch in a Can™ technology with Moberg’s Kaprolac® platform should produce an exciting, novel product for the global dermatology market which is greatly needed. It will be great to collaborate with an up and coming EU dermatology company”, adds Andrew Muddle, CEO of MedPharm Ltd.
Contact Moberg Derma Peter Wolpert, President and CEO Telephone: +46 8 522 307 08 Mobile: +46 70 735 71 35 E-mail: email@example.com Contact MedPharm Andrew Muddle, CEO Telephone: + 44 1483 447744 Mobile: +44 7939 240 957 E-mail: firstname.lastname@example.org
About Moberg Derma Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of common skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining promotion rights for the Nordic region. The company began operations at the Karolinska Institute in 2006 and currently has 10 employees. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: www.mobergderma.se About Kaprolac® Moberg Derma’s Kaprolac® technology is a composition of well-known and safe dermatological compounds which provides important therapeutic benefits. Kaprolac® provides a unique combination of properties for dermatological products, a potent antimicrobial effect as well as keratolytic and moisturizing properties with an excellent safety profile.
About MedPharm MedPharm Ltd is a private drug delivery and contract service company committed to the creation and development of novel systems, particularly for topical drug formulations for delivery to the skin, nail, mucous membranes, eye, nose and lung. MedPharm has a reputation for success with formulating difficult compounds especially in the area of topical drug delivery. MedPharm was founded in 1999 and is located in Guildford, Surrey, United Kingdom. For further information, please visit: www.medpharm.co.uk About MedSpray MedSpray™ is a patented self-assembling Patch in a Can® technology which optimizes topical and transdermal drug delivery by overcoming the barrier properties of the stratum corneum. MedSpray™ provides a sprayable pharmaceutical formulation capable of forming a microthin film on topical administration that simply washes off after use, if required. The properties of the film can be manipulated to achieve the required drug delivery and film properties in terms of tackiness, viscosity and water resistance.